Oestrogen-synthesising enzymes and breast cancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Anticancer Research

• Publication date

  2009-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 19414351
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity.

  2008cited by this paper
• The Role of the Immune System

  2008cited by this paper
• Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer

  2008cited by this paper
• Sulfotransferase 2B1b in human breast: differences in subcellular localization in African American and Caucasian women.

  2008cited by this paper
• Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.

  2008cited by this paper
• Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells.

  2007cited by this paper
• C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation.

  2007cited by this paper
• Perinatal Bisphenol A Exposure Increases Estrogen Sensitivity of the Mammary Gland in Diverse Mouse Strains

  2007cited by this paper
• Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

  2007cited by this paper
• Dual aromatase-sulfatase inhibitors based on the anastrozole template: synthesis, in vitro SAR, molecular modelling and in vivo activity (vol 5, pg 2940, 2007)

  2007cited by this paper
• Dual aromatase-steroid sulfatase inhibitors.

  2007cited by this paper
• Induction of mammary gland ductal hyperplasias and carcinoma in situ following fetal bisphenol A exposure.

  2007cited by this paper
• The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome in human breast cancer

  2006cited by this paper
• Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1.

  2006cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• In vivo Efficacy of STX213, A Second-Generation Steroid Sulfatase Inhibitor, for Hormone-Dependent Breast Cancer Therapy

  2006cited by this paper
• Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor

  2006cited by this paper
• International Seminars in Surgical Oncology Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer in the Era of Aromatase Inhibitors: an Update

  2006cited by this paper
• The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.

  2006cited by this paper
• The role of aromatase and 17-β-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer

  2006cited by this paper
• Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts.

  2006cited by this paper
• A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity.

  2005cited by this paper
• Steroid sulfatase: molecular biology, regulation, and inhibition.

  2005cited by this paper
• A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

  2005cited by this paper
• Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.

  2005cited by this paper
• E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.

  2005cited by this paper
• Immunohistochemical evaluation of cytochrome P450 (CYP) and p53 in breast cancer.

  2005cited by this paper
• Perinatal exposure to bisphenol-A alters peripubertal mammary gland development in mice.

  2005cited by this paper
• Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells

  2005cited by this paper
• The Higher Affinity of Human Type 1 3β‐Hydroxysteroid Dehydrogenase (3β‐HSD1) for Substrate and Inhibitor Steroids Relative to Human 3β‐HSD2 is Validated in MCF‐7 Tumor Cells and Related to Subunit Interactions

  2004cited by this paper
• 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.

  2004cited by this paper
• 17β-Hydroxysteroid Dehydrogenase Type 1 Is an Independent Prognostic Marker in Breast Cancer

  2004cited by this paper
• The selective estrogen enzyme modulators in breast cancer: a review.

  2004cited by this paper
• Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity.

  2003cited by this paper
• Sources of estrogen and their importance.

  2003cited by this paper
• Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast

  2003cited by this paper
• Synthesis of a First Estradiol-Adenosine Hybrid Compound

  2003cited by this paper
• Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells.

  2003cited by this paper
• Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone.

  2003cited by this paper
• A Potential Role for the Estrogen-metabolizing Cytochrome P450 Enzymes in Human Breast Carcinogenesis

  2003cited by this paper
• Amplification of HSD17B1 and ERBB2 in primary breast cancer

  2003cited by this paper
• Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma.

  2003cited by this paper
• Cytochrome p450 and glutathione transferase expression in human breast cancer.

  2003cited by this paper
• Steroid sulphatase inhibitors for breast cancer therapy.

  2003cited by this paper
• Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates.

  2003cited by this paper
• High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.

  2003cited by this paper
• Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.

  2003cited by this paper
• Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue.

  2002cited by this paper
• Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast

  2002cited by this paper
• Transcriptional activation by the oestrogen receptor α is modulated through inhibition of cyclin-dependent kinases

  2002cited by this paper
• Anastozole (A) is superior to tamoxifen (T) in treatment of postmenopausal (PM) women with early breast cancer (EBC) - First results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial (on behalf of the ATAC Trialists' Group)

  2002cited by this paper
• The evolving role of aromatase inhibitors in breast cancer

  2002cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

  2002cited by this paper
• Aromatase--a brief overview.

  2002cited by this paper
• Molecular and biochemical characterisation of a novel sulphatase gene: Arylsulfatase G (ARSG)

  2002cited by this paper
• A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project.

  2001cited by this paper
• Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates.

  2001cited by this paper
• Estrogen production and action.

  2001cited by this paper
• The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue

  2001cited by this paper
• Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.

  2001cited by this paper
• Aromatase Inhibitors

  2001cited by this paper
• High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.

  2001cited by this paper
• Regulation of steroid sulphatase expression and activity in breast cancer.

  2000cited by this paper
• Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues.

  2000cited by this paper
• 17 β -Hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters

  2000cited by this paper
• Is Estradiol a Genotoxic Mutagenic Carcinogen ? *

  2000cited by this paper
• 17β-Hydroxysteroid Dehydrogenase Type 1 and 2 Expression in the Human Fetus1

  2000cited by this paper
• Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells.

  2000cited by this paper
• Elevated steroid sulfatase expression in breast cancers.

  2000cited by this paper
• 17beta-hydroxysteroid dehydrogenase type 1 and 2 expression in the human fetus.

  2000cited by this paper
• In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE.

  2000cited by this paper
• Is estradiol a genotoxic mutagenic carcinogen?

  2000cited by this paper
• 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.

  2000cited by this paper
• Multiple Signaling Pathways Mediate Interleukin-4-Induced 3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4 Isomerase Type 1 Gene Expression in Human Breast Cancer Cells

  2000cited by this paper
• Immunohistochemical Localization of Cytochrome P450 CYP1B1 in Breast Cancer with Monoclonal Antibodies Specific for CYP1B1

  1999cited by this paper
• Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer.

  1999cited by this paper
• Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13.

  1999cited by this paper
• The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2.

  1999cited by this paper
• Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha.

  1999cited by this paper
• 17β-Hydroxysteroid Dehydrogenase Types 1 and 2 in Human Placenta: An Immunohistochemical Study with Correlation to Placental Development1

  1998cited by this paper
• 17Beta-hydroxysteroid dehydrogenase types 1 and 2 in human placenta: an immunohistochemical study with correlation to placental development.

  1998cited by this paper
• Expression of 3β-hydroxysteroid dehydrogenase-5,4-en isomerase activity by infiltrating ductal human breast carcinoma in vitro

  1998cited by this paper
• Intratumoral aromatase in human breast, endometrial, and ovarian malignancies.

  1998cited by this paper
• Induction of 3 b-Hydroxysteroid Dehydrogenase / D 5D 4 Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13

  1998cited by this paper
• Aromatase and breast cancer.

  1998cited by this paper
• Human estrogen sulfotransferase (hEST1) activities and its mRNA in various breast cancer cell lines. Effect of the progestin, promegestone (R-5020).

  1998cited by this paper
• C16 and C17 derivatives of estradiol as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships.

  1998cited by this paper
• In situ aromatization enhances breast tumor estradiol levels and cellular proliferation.

  1998cited by this paper
• Transcriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture.

  1997cited by this paper
• Characterization of Point Mutations in Patients with X-linked Ichthyosis

  1997cited by this paper
• Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women.

  1997cited by this paper
• Control of aromatase activity in breast tumours: the role of the immune system.

  1997cited by this paper
• Aromatase in the normal breast and breast cancer.

  1997cited by this paper
• Aromatase in Human Bone Tissue

  1997cited by this paper
• Endocrine disorders associated with inappropriately high aromatase expression.

  1997cited by this paper
• Environmental estrogen stimulation of growth and estrogen receptor function in preneoplastic and cancerous human breast cell lines.

  1997cited by this paper
• Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines.

  1997cited by this paper
• Structure of a human lysosomal sulfatase.

  1997cited by this paper
• Expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage

  1997cited by this paper
• Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma.

  1996cited by this paper

• Cell Progression and Survival Functions of Enzymes Secreted in Extracellular Vesicles Associated with Breast and Prostate Cancers

  2025cites this paper
• Investigation of anticancer potential of a novel bioactive molecule from Trichosporon asahii VITSTB1 in breast cancer cell lines: an in vitro study

  2024cites this paper
• Unraveling anticancer potential of a novel serine protease inhibitor from marine yeast Candida parapsilosis ABS1 against colorectal and breast cancer cells

  2023cites this paper
• Prognostic Value of Intracellular Transcription of Factors HIF-1α and p53 and Their Relation to Estradiol and TNM Parameters of Breast Cancer Tissues in Women with Invasive Ductal Carcinoma in Thi-Qar Province, Iraq.

  2022cites this paper
• Esr1 but Not CYP19A1 Overexpression in Mammary Epithelial Cells during Reproductive Senescence Induces Pregnancy-Like Proliferative Mammary Disease Responsive to Anti-Hormonals.

  2022cites this paper
• CC chemokine ligand 2 (CCL2) stimulates aromatase gene expression in mammary adipose tissue

  2021cites this paper
• Estrone Sulfatase Inhibitors as New Anticancer Agents

  2019cites this paper
• Dairy Food Consumption and Mammographic Breast Density: The Role of Fat

  2019cites this paper
• The Role of Breast Cancer Chemoprevention in High-Risk Women

  2018cites this paper
• Human steroid sulfatase induces Wnt/β-catenin signaling and epithelial-mesenchymal transition by upregulating Twist1 and HIF-1α in human prostate and cervical cancer cells

  2017cites this paper
• Adiposity, breast density, and breast cancer risk: epidemiological and biological considerations

  2017cites this paper
• Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer

  2016cites this paper
• Synthesis of anticancer drug anastrozole via phase-transfer catalyst

  2015cites this paper
• Breast cancer treatment and sulfotransferase

  2015cites this paper
• Identifying the molecular mediators of VN and the IGF:VN complex-stimulated breast cancer cell survival

  2015cites this paper
• Nonsteroidal aromatase inhibitors for the treatment of breast cancer: an update.

  2014cites this paper
• Lack of genomic rearrangements involving the aromatase gene CYP19A1 in breast cancer

  2014cites this paper
• Serum glucose and risk of cancer: a meta-analysis

  2014cites this paper
• Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study

  2014cites this paper
• Toremifene in premenstrual mastalgia

  2013cites this paper
• Exploring the role of CD44 in tamoxifen resistant breast cancer

  2013cites this paper
• The Effect of Grapefruit Intake on Endogenous Serum Estrogen Levels in Postmenopausal Women

  2013cites this paper
• Impact of testosterone on the expression of organic anion transporting polypeptides (OATP-1A2, OATP-2B1, OATP-3A1) in malignant and non-malignant human breast cells in vitro.

  2012cites this paper
• Aromatase and steroid sulfatase mRNA expression in fine needle aspirates from benign and malignant breast disorders

  2012cites this paper
• Epigenetic events associated with breast cancer and their prevention by dietary components targeting the epigenome.

  2012cites this paper
• Accelerating the Application of ERα Cofactor in the Therapy of Breast Cancer

  2012cites this paper
• Endocrine therapy of breast cancer.

  2011cites this paper
• Estrogen pathway polymorphisms and mammographic density.

  2011cites this paper
• Estrogen receptor β signalling in mammary epithelial and breast cancer cells

  2010cites this paper
• Hormone replacement therapy (HRT), breast cancer and tumor pathology.

  2010cites this paper
• Particular functions of estrogen and progesterone in establishment of uterine receptivity and embryo implantation.

  2010cites this paper
• Polymorphisms in genes involved in the estrogen pathway and mammographic density

  2010cites this paper
• Molecular therapy of breast cancer: progress and future directions

  2010cites this paper